Truncated Fragments Of Alpha-synuclein In Lewy Body Disease


The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.

CPC Classifications
Download PDF
Document Preview
Document History
  • Publication: Apr 15, 2008
  • Application: Jul 29, 2005
    US US 19411505 A
  • Priority: Jul 29, 2005
    US US 19411505 A
  • Priority: Oct 19, 2004
    US US 96933504 A
  • Priority: May 19, 2004
    US US 85057004 A
  • Priority: May 19, 2004
    US US 2004/0015836 W
  • Priority: May 19, 2003
    US US 47192903 P

Download Citation

Sign in to the Lens